170 related articles for article (PubMed ID: 26731131)
1. Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain.
Chaikuad A; Lang S; Brennan PE; Temperini C; Fedorov O; Hollander J; Nachane R; Abell C; Müller S; Siegal G; Knapp S
J Med Chem; 2016 Feb; 59(4):1648-53. PubMed ID: 26731131
[TBL] [Abstract][Full Text] [Related]
2. Unravelling novel congeners from acetyllysine mimicking ligand targeting a lysine acetyltransferase PCAF bromodomain.
Suryanarayanan V; Singh SK
J Biomol Struct Dyn; 2018 Dec; 36(16):4303-4319. PubMed ID: 29228881
[TBL] [Abstract][Full Text] [Related]
3. Current development of CBP/p300 inhibitors in the last decade.
He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
[TBL] [Abstract][Full Text] [Related]
4. Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors.
Popp TA; Tallant C; Rogers C; Fedorov O; Brennan PE; Müller S; Knapp S; Bracher F
J Med Chem; 2016 Oct; 59(19):8889-8912. PubMed ID: 27673482
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
[TBL] [Abstract][Full Text] [Related]
6. Another One (of the "Undruggable" Targets) Bites the Dust: Discovery of a Potent and Selective Inhibitor of the Histone Acetyl Transferase p300/CBP.
Kodadek T
Biochemistry; 2018 Feb; 57(6):899-900. PubMed ID: 29244478
[No Abstract] [Full Text] [Related]
7. Fluorescence polarization for the evaluation of small-molecule inhibitors of PCAF BRD/Tat-AcK50 association.
Hu P; Wang X; Zhang B; Zhang S; Wang Q; Wang Z
ChemMedChem; 2014 May; 9(5):928-31. PubMed ID: 24474698
[TBL] [Abstract][Full Text] [Related]
8. Structure based identification and biological evaluation of novel and potent inhibitors of PCAF catalytic domain.
Suryanarayanan V; Rajavel T; Devi KP; Singh SK
Int J Biol Macromol; 2018 Dec; 120(Pt A):823-834. PubMed ID: 30118769
[TBL] [Abstract][Full Text] [Related]
9. Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain.
Unzue A; Xu M; Dong J; Wiedmer L; Spiliotopoulos D; Caflisch A; Nevado C
J Med Chem; 2016 Feb; 59(4):1350-6. PubMed ID: 26043365
[TBL] [Abstract][Full Text] [Related]
10. Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome.
Weinert BT; Narita T; Satpathy S; Srinivasan B; Hansen BK; Schölz C; Hamilton WB; Zucconi BE; Wang WW; Liu WR; Brickman JM; Kesicki EA; Lai A; Bromberg KD; Cole PA; Choudhary C
Cell; 2018 Jun; 174(1):231-244.e12. PubMed ID: 29804834
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of PCAF suppresses microglial-mediated β-amyloid neurotoxicity.
Park SY; Lee YH; Seong AR; Lee J; Jun W; Yoon HG
Int J Mol Med; 2013 Aug; 32(2):469-75. PubMed ID: 23740527
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300.
Zeng L; Zhang Q; Gerona-Navarro G; Moshkina N; Zhou MM
Structure; 2008 Apr; 16(4):643-52. PubMed ID: 18400184
[TBL] [Abstract][Full Text] [Related]
14. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA
Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021
[TBL] [Abstract][Full Text] [Related]
15. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
Picaud S; Fedorov O; Thanasopoulou A; Leonards K; Jones K; Meier J; Olzscha H; Monteiro O; Martin S; Philpott M; Tumber A; Filippakopoulos P; Yapp C; Wells C; Che KH; Bannister A; Robson S; Kumar U; Parr N; Lee K; Lugo D; Jeffrey P; Taylor S; Vecellio ML; Bountra C; Brennan PE; O'Mahony A; Velichko S; Müller S; Hay D; Daniels DL; Urh M; La Thangue NB; Kouzarides T; Prinjha R; Schwaller J; Knapp S
Cancer Res; 2015 Dec; 75(23):5106-5119. PubMed ID: 26552700
[TBL] [Abstract][Full Text] [Related]
16. Dual Labeling of the CBP/p300 KIX Domain for
Gee CT; Arntson KE; Koleski EJ; Staebell RL; Pomerantz WCK
Chembiochem; 2018 May; 19(9):963-969. PubMed ID: 29430847
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe.
Humphreys PG; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Hayhow TG; Hussain J; Jones KL; Lindon M; Michon AM; Renaux JF; Suckling CJ; Tough DF; Prinjha RK
J Med Chem; 2017 Jan; 60(2):695-709. PubMed ID: 28002667
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
19. A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors.
Bronner SM; Murray J; Romero FA; Lai KW; Tsui V; Cyr P; Beresini MH; de Leon Boenig G; Chen Z; Choo EF; Clark KR; Crawford TD; Jayaram H; Kaufman S; Li R; Li Y; Liao J; Liang X; Liu W; Ly J; Maher J; Wai J; Wang F; Zheng A; Zhu X; Magnuson S
J Med Chem; 2017 Dec; 60(24):10151-10171. PubMed ID: 29155580
[TBL] [Abstract][Full Text] [Related]
20. Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics.
Xu M; Unzue A; Dong J; Spiliotopoulos D; Nevado C; Caflisch A
J Med Chem; 2016 Feb; 59(4):1340-9. PubMed ID: 26125948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]